Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2–5 years in China

The widespread use of pneumococcal conjugate vaccines (PCVs) has significantly decreased pneumococcal disease worldwide. However, China has not adopted PCVs in their national immunization schedules and had only approved these vaccines for children aged 2–15 months by 2020. In an open-label trial, en...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2021-06, Vol.39 (25), p.3428-3434
Main Authors: Wang, Jian, Bai, Shuang, Zhou, Shanshan, Zhao, Wei, Li, Qin, Lv, Min, Zhang, Peng, Zhang, Haizhou, Lan, Wenwen, Kang, Yanli, Wang, Yali, Li, Jin, Gao, Xiaotong, Tong, Xiaomei, Wu, Jiang, Zheng, Qun
Format: Article
Language:English
Subjects:
Adverse events
Age
Age groups
Antibodies
Children
Conjugates
Disease
Immunization
Immunogenicity
Immunoglobulin G
PCV7
Pneumonia
Population
Preexisting antibodies
Safety
Schedules
Serotypes
Streptococcus infections
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The widespread use of pneumococcal conjugate vaccines (PCVs) has significantly decreased pneumococcal disease worldwide. However, China has not adopted PCVs in their national immunization schedules and had only approved these vaccines for children aged 2–15 months by 2020. In an open-label trial, enrolled healthy children aged 2–5 years old were randomized 1:1 and divided into a 7-valent pneumococcal conjugate vaccine (PCV7) group and a Haemophilus influenzae type b conjugate vaccine (Hib) group. Children in the PCV7 group received a single dose of PCV7, and the Hib group received a single dose of Hib vaccine. Blood samples were collected before and 6 months after vaccination. Immunogenicity and safety of PCV7 were assessed at prespecified time points. Six months after a single dose of PCV7, children in the PCV7 group for all 7 serotypes, IgG mean concentrations (GMCs) and opsonophagocytic geometric mean titres (GMTs) were significantly higher (P 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2021.04.037